---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000060"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:08:39.261889+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics provides 2024 pipeline update: ATRN-119 dose escalation ongoing, IND for APR-1051 expected Q1 2024

## Summary
- Phase 1/2a trial of ATRN-119 continues; two patients achieved stable disease at 50 mg and 200 mg doses.
- Dose-limiting toxicity period for 350 mg cohort completed; RP2D expected H2 2024.
- IND submission for next-gen WEE1 inhibitor APR-1051 being finalized; FDA clearance expected Q1 2024.
- Preclinical data for APR-1051 show improved selectivity and reduced off-target effects vs other WEE1 inhibitors.
- Company to hold investor meetings at LifeSci Partners Corporate Access Event on Jan 10, 2024.

## SEC filing metadata
- accession: 0001558370-24-000060
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837024000060/0001558370-24-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837024000060/apre-20240104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000060
- JSON: https://secwatch.observer/filing/0001558370-24-000060.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.